Referred to the House Committee on Energy and Commerce.
The bill bars any Federal funds from being used to implement, administer, or enforce the FDA final rule titled “Medical Devices; Laboratory Developed Tests” submitted May 6, 2024 (89 Fed. Reg. 37286), or any substantially similar rule.
Safety oversight vs. regulatory burden for clinical laboratories.
Narrow, symbolic funding restriction often passes lower chamber as standalone or rider when aligned with majority priorities.
The bill bars any Federal funds from being used to implement, administer, or enforce the FDA final rule titled “Medical Devices; Laboratory Developed Tests” submitted May 6, 2024 (89 Fed.
Reg. 37286), or any substantially similar rule.
Narrow and administratively specific bills often pass one chamber but fail to survive Senate/Executive review absent broader consensus or inclusion in appropriations compromise.
How solid the drafting looks.
Safety oversight vs. regulatory burden for clinical laboratories.
These are examples from the analysis, not a ranked list of the most-affected groups.
Safety oversight vs. regulatory burden for clinical laboratories.
Likely to oppose the bill because it blocks federal safety oversight of laboratory-developed tests (LDTs).
They will emphasize patient protection, equitable access to validated tests, and the role of FDA in regulating medical devices.
Some concerns about access or innovation impacts from the FDA rule may be acknowledged, but safety and standards will predominate.
Mixed view: supports patient safety and clear standards but worries about excessive regulatory burden on clinical labs.
Will weigh evidence for the FDA rule’s benefits against costs to lab capacity and access.
May prefer targeted fixes or time-limited funding prohibition while Congress examines impacts.
Likely to strongly support the bill as a check on FDA regulatory expansion.
Emphasizes reducing federal overreach, protecting local labs, lowering regulatory compliance costs, and preserving access to tests.
Views a funding prohibition as an effective tool to halt an unwanted federal rule.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow and administratively specific bills often pass one chamber but fail to survive Senate/Executive review absent broader consensus or inclusion in appropriations compromise.
The bill has not accumulated any surfaced votes yet.
Safety oversight vs. regulatory burden for clinical laboratories.
Narrow and administratively specific bills often pass one chamber but fail to survive Senate/Executive review absent broader consensus or i…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for To prohibit the use of Federal funds to implement, administer,…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.